MY207877A - Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide - Google Patents

Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Info

Publication number
MY207877A
MY207877A MYPI2022000419A MYPI2022000419A MY207877A MY 207877 A MY207877 A MY 207877A MY PI2022000419 A MYPI2022000419 A MY PI2022000419A MY PI2022000419 A MYPI2022000419 A MY PI2022000419A MY 207877 A MY207877 A MY 207877A
Authority
MY
Malaysia
Prior art keywords
carboxamide
acetyl
pyridine
chloro
tert
Prior art date
Application number
MYPI2022000419A
Other languages
English (en)
Inventor
Collingwood Stephen
MELLING Robert
Original Assignee
Tmem16A Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tmem16A Ltd filed Critical Tmem16A Ltd
Publication of MY207877A publication Critical patent/MY207877A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
MYPI2022000419A 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide MY207877A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1910664.0A GB201910664D0 (en) 2019-07-25 2019-07-25 Novel forms of compound
PCT/GB2020/051779 WO2021014167A1 (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Publications (1)

Publication Number Publication Date
MY207877A true MY207877A (en) 2025-03-25

Family

ID=67990591

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2022000419A MY207877A (en) 2019-07-25 2020-07-24 Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide

Country Status (19)

Country Link
US (1) US12281077B2 (https=)
EP (1) EP4003960A1 (https=)
JP (1) JP7627683B2 (https=)
KR (1) KR20220087430A (https=)
CN (1) CN114585607B (https=)
AU (1) AU2020318943A1 (https=)
BR (1) BR112022001276A2 (https=)
CA (1) CA3145285A1 (https=)
CL (1) CL2022000187A1 (https=)
CO (1) CO2022002046A2 (https=)
CR (2) CR20220079A (https=)
GB (1) GB201910664D0 (https=)
IL (1) IL290071B1 (https=)
MX (1) MX2022000891A (https=)
MY (1) MY207877A (https=)
PE (1) PE20221407A1 (https=)
PH (1) PH12022550193A1 (https=)
UA (1) UA129300C2 (https=)
WO (1) WO2021014167A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050176767A1 (en) * 2003-10-30 2005-08-11 Laval Chan Chun Kong Pyridine carboxamide and methods for inhibiting HIV integrase
CA2658362A1 (en) 2006-06-29 2008-01-03 Alantos Pharmaceuticals Holding, Inc. Metalloprotease inhibitors
WO2016042114A1 (en) * 2014-09-19 2016-03-24 F. Hoffmann-La Roche Ag Cxcl14 as a biomarker of hedgehog pathway activity for the diagnosis, prognosis and treatment of idiopathic pulmonary fibrosis
US11358947B2 (en) 2017-04-17 2022-06-14 The Regents Of The University Of California Substituted 2-acylamino-cycloalkylthiophene-3-carboxylic acid arylamides as inhibitors of calcium-activated chloride channel TMEM16A
GB201801355D0 (en) * 2018-01-26 2018-03-14 Enterprise Therapeutics Ltd Compounds

Also Published As

Publication number Publication date
CA3145285A1 (en) 2021-01-28
GB201910664D0 (en) 2019-09-11
IL290071B1 (en) 2026-02-01
AU2020318943A1 (en) 2022-03-17
JP2022542918A (ja) 2022-10-07
BR112022001276A2 (pt) 2022-03-22
JP7627683B2 (ja) 2025-02-06
KR20220087430A (ko) 2022-06-24
PH12022550193A1 (en) 2023-01-09
MX2022000891A (es) 2022-05-26
EP4003960A1 (en) 2022-06-01
US20220220074A1 (en) 2022-07-14
US12281077B2 (en) 2025-04-22
CN114585607B (zh) 2025-11-14
CL2022000187A1 (es) 2022-10-07
CO2022002046A2 (es) 2022-06-10
CR20220079A (es) 2022-06-28
CR20250316A (es) 2025-08-27
UA129300C2 (uk) 2025-03-12
CN114585607A (zh) 2022-06-03
IL290071A (en) 2022-03-01
WO2021014167A1 (en) 2021-01-28
PE20221407A1 (es) 2022-09-20

Similar Documents

Publication Publication Date Title
EP4480483A3 (en) Solid state forms of belumosudil and belumosudil salts
MX2010002836A (es) Bortezomib y proceso para la produccion del mismo.
MX2021008002A (es) Sales nuevas y forma polimorfica del acido bempedoico.
WO2012004396A3 (en) Process of preparing a thrombin specific inhibitor
GB202101909D0 (en) Novel crystalline form of pyroxa-sulfone, methods for its preparation and use of the same
EP3986870A4 (en) NEW CRYSTALLINE FORM OF OLAPARIB AND PROCESS OF PRODUCTION
EP4480538A3 (en) Solid state forms of mavacamten and process for preparation thereof
GEP20094576B (en) New cyrstalline form iii of agomelatine, a process for its preparation and pharmaceutical compositions containing it
MY198008A (en) Crystal of benzofuran derivative free base and preparation method
SG11202108863WA (en) Crystalline pyrimidinyl-3,8-diazabicyclo[3.2.1]octanylmethanone compound and use thereof
EP4353230A3 (en) Solid state forms of asciminib and process for preparation thereof
PH12021550456A1 (en) Crystalline forms of a quinazole compound and its hydrochloride salts
TW200640886A (en) Crystalline forms of linezolid intermediate
MY207877A (en) Solid forms of n-tert-butyl-4[[2-(5-chloro-2-hydroxy-phneyl)acetyl]amino]pyridine-2-carboxamide
ZA202205170B (en) Process and intermediate for the preparation of oxetan-2-ylmethanamine
ZA200800138B (en) Process for the preparation of crystalline perindopril
WO2021107522A3 (ko) 알룰로스 제조용 조성물 및 이를 이용한 알룰로스의 제조 방법
MX2024003904A (es) Formas cristalinas de moduladores de los canales de potasio.
AU2024290368A1 (en) Crystalline form
WO2020012408A3 (en) A process for purification of protected polycyclic carbamoylpyridone derivatives
WO2019215753A3 (en) Process for preparation of pure plecanatide
MX2023008883A (es) Polimorfo de diclorhidrato de latrepirdina.
WO2014195977A3 (en) Novel polymorphs of vismodegib
WO2012038971A3 (en) Novel polymorphs of febuxostat
PH12020500385A1 (en) A process for preparation of triaminopyrimidine compound and intermediates thereof